UBS Group
NYMX

UBS Group’s Nymox Pharmaceutical Corp NYMX Stock Holding History

UBS Group’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-16,000
Closed -$70K – 8096
2017
Q2 		$70K Buy
+16,000
New +$65.7K ﹤0.01% 5423

Other funds holding NYMX

DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
CAM
Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return
ODIJL
One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

UBS Group's NYMX Position: Q3 2023 in Review

UBS Group sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 34,530 shares — an estimated $6.56K sold.

UBS Group first reported a position in NYMX in Q4 2014 and held it in 33 quarters. The position peaked at $119K in Q2 2017. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

  • UBS Group reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 34,530 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $6.56K.
  • UBS Group first reported a position in Nymox Pharmaceutical Corp in Q4 2014 and held it in 33 quarters.
  • UBS Group's Nymox Pharmaceutical Corp position peaked at $119K in Q2 2017.
  • 5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.